Clinical and non-invasive assessment of metabolic dysfunction-associated steatotic liver disease and glycogenic hepatopathy in individuals with type 1 diabetes

Clicks: 18
ID: 332019
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #268 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective To deepen understanding of metabolic dysfunction-associated steatotic liver disease (MASLD) and presumptive glycogenic hepatopathy (GH) in adults with type 1 diabetes (T1D), and to evaluate non-invasive indices and novel biomarkers for their differentiation. Methods We conducted a cross-sectional study including 202 adults with T1D. Hepatic steatosis was assessed using a stepwise imaging approach: all participants underwent ultrasound (US); liver magnetic resonance imaging-proton density fat fraction (MRI-PDFF) was performed when US was abnormal. Based on imaging, participants were categorized into three hepatic phenotypes: normal liver (NL), MASLD (steatosis on both US and MRI), and presumptive GH (hyperechogenicity on US but <5% fat on MRI). MRI-derived fat correlations and the performance of non-invasive indices and biomarkers were assessed. Results Hepatic steatosis was identified by US in 39 participants, yielding a MASLD prevalence of 19.3%. Among the 32 participants with abnormal US who underwent MRI-PDFF, only 50% had liver fat ≥5%, indicating limited specificity of US and enabling identification of a presumptive GH phenotype (8.2%). MASLD was associated with a worse metabolic profile than presumptive GH or NL. The Fatty Liver Index (FLI) correlated strongly with MRI liver fat (ρ = 0.726, p < 0.0001) and showed promising exploratory performance (AUC = 0.842, 95% CI 0.687–0.998). Conclusions US may overestimate hepatic steatosis in adults with T1D, partly due to presumptive GH. Among participants undergoing MRI-PDFF, FLI showed promising exploratory performance for identifying steatosis, but requires further validation in cohorts undergoing systematic MRI-PDFF assessment.
Reference Key
openalex_W7221364446 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sílvia Ballesta, Juan Pedro-Botet, Elisenda Climent, Sonia Fernández‐Veledo, R Gaja, Anna Garrido, Joan Josep Vendrell, Juan Sánchez, Mercè Fernández, Juan José Chillarón, Gemma Llauradó
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag422
URL
https://doi.org/10.1210/clinem/dgag422
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.